Suppr超能文献

血清载脂蛋白 B 浓度升高与糖尿病肾病患者进入肾脏替代治疗的风险增加相关。

Increased serum concentration of apolipoprotein B is associated with an increased risk of reaching renal replacement therapy in patients with diabetic kidney disease.

机构信息

Department of Nephrology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

出版信息

Ren Fail. 2020 Nov;42(1):323-328. doi: 10.1080/0886022X.2020.1745235.

Abstract

Few studies have investigated the association of apolipoprotein B (ApoB) with the progression of diabetic kidney disease (DKD) and the risk of renal replacement therapy (RRT). In this retrospective cohort study, a group of 258 DKD patients with stage 3-5chronic kidney disease(CKD)were divided into low ApoB (<1.1 g/L) and high ApoB (≥1.1 g/L) groups and followed-up for 20.51 ± 6.11 months. The association of the serum ApoB concentration with RRT was determined by Kaplan-Meier and Cox regression analysis. ApoB was measured in the serum. Ninety-three of the 258 DKD patients needed RRT during follow-up. Kaplan-Meier analysis showed that patients with high ApoB were significantly more likely to progress to RRT than those with low ApoB (log-rank = 16.62,  < 0.001). The presence of high ApoB increased the risk of RRT. Analysis of ApoB as either a categorical (<1.1 g/L or ≥1.1 g/l) or continuous variable by univariate and multivariate regression found that ApoB was an independent risk factor of DKD progression to RRT in this group of DKD patients with stage 3-5 CKD ( < 0.05). Increased ApoB was an independent predictor of progression to RRT. A larger study is needed to confirm the unfavorable prognosis of increased ApoB in DKD patients.

摘要

很少有研究调查载脂蛋白 B (ApoB) 与糖尿病肾病 (DKD) 进展和肾脏替代治疗 (RRT) 风险的关系。在这项回顾性队列研究中,将 258 例患有 3-5 期慢性肾脏病 (CKD) 的 DKD 患者分为低 ApoB(<1.1g/L) 和高 ApoB(≥1.1g/L) 组,并随访 20.51±6.11 个月。通过 Kaplan-Meier 和 Cox 回归分析确定血清 ApoB 浓度与 RRT 的关系。检测血清中的 ApoB。在随访期间,258 例 DKD 患者中有 93 例需要 RRT。Kaplan-Meier 分析显示,高 ApoB 组患者进展为 RRT 的可能性明显高于低 ApoB 组(log-rank = 16.62, < 0.001)。高 ApoB 的存在增加了 RRT 的风险。通过单因素和多因素回归分析将 ApoB 作为分类变量(<1.1g/L 或≥1.1g/L)或连续变量进行分析,发现 ApoB 是该组 3-5 期 CKD DKD 患者进展为 RRT 的独立危险因素( < 0.05)。ApoB 升高是 RRT 进展的独立预测因子。需要更大的研究来证实 ApoB 升高对 DKD 患者预后不利。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21aa/7170318/ec0719bbd309/IRNF_A_1745235_F0001_C.jpg

相似文献

2
Serum apolipoprotein B/apolipoprotein A1 ratio is associated with the progression of diabetic kidney disease to renal replacement therapy.
Int Urol Nephrol. 2020 Oct;52(10):1923-1928. doi: 10.1007/s11255-020-02550-7. Epub 2020 Jul 13.
3
Mortality and Renal Replacement Therapy after Renal Artery Stent Placement for Atherosclerotic Renovascular Disease.
J Vasc Interv Radiol. 2016 Aug;27(8):1215-24. doi: 10.1016/j.jvir.2016.05.001. Epub 2016 Jun 11.
7
Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
J Diabetes Complications. 2016 Sep-Oct;30(7):1300-7. doi: 10.1016/j.jdiacomp.2016.06.002. Epub 2016 Jun 7.
8
Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy.
Scand J Urol Nephrol. 2012 Apr;46(2):148-55. doi: 10.3109/00365599.2011.644635. Epub 2012 Jan 3.
9
Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients.
PLoS One. 2016 Aug 22;11(8):e0159914. doi: 10.1371/journal.pone.0159914. eCollection 2016.

引用本文的文献

2
New composite phenotypes enhance chronic kidney disease classification and genetic associations.
PLoS Genet. 2025 May 23;21(5):e1011718. doi: 10.1371/journal.pgen.1011718. eCollection 2025 May.
4
Development and validation of a predictive model for end-stage renal disease in systemic lupus erythematosus patients.
Rheumatol Int. 2024 Oct;44(10):1941-1958. doi: 10.1007/s00296-024-05686-2. Epub 2024 Aug 21.
7
The Roles of Fatty Acids and Apolipoproteins in the Kidneys.
Metabolites. 2022 May 20;12(5):462. doi: 10.3390/metabo12050462.
8
Elevated serum cholesterol levels are associated with proteinuria over 0.5 g/day in premenopausal women with systemic lupus erythematosus.
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221101287. doi: 10.1177/03946320221101287.

本文引用的文献

1
Triglycerides and cardiovascular risk: Apolipoprotein B holds the key.
Atherosclerosis. 2019 May;284:221-222. doi: 10.1016/j.atherosclerosis.2019.03.004. Epub 2019 Mar 21.
2
Association Between the Lipid Profile and Renal Dysfunction in the Heart Failure Patients.
Kidney Blood Press Res. 2019;44(1):52-61. doi: 10.1159/000498834. Epub 2019 Feb 22.
4
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
5
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.
Toxins (Basel). 2016 Dec 16;8(12):376. doi: 10.3390/toxins8120376.
6
LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
Atherosclerosis. 2016 Aug;251:170-176. doi: 10.1016/j.atherosclerosis.2016.06.029. Epub 2016 Jun 16.
7
Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.
Clin J Am Soc Nephrol. 2014 Jul;9(7):1190-8. doi: 10.2215/CJN.09320913. Epub 2014 May 15.
9
Prevalence of chronic kidney disease in China: a cross-sectional survey.
Lancet. 2012 Mar 3;379(9818):815-22. doi: 10.1016/S0140-6736(12)60033-6.
10
New insights into lipid metabolism in chronic kidney disease.
J Ren Nutr. 2011 Jan;21(1):120-3. doi: 10.1053/j.jrn.2010.10.017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验